Treatment with Met-RANTES decreases bacterial translocation in experimental colitis

American Journal of Surgery

Volumn 191, Issue 1, 2006, Pages 77-83

  Kucuk, Can ^a   Sozuer, Erdogan ^a   Gursoy, Sebnem ^a   Canoz, Ozlem ^a   Artis, Tarik ^a   Akcan, Alper ^a   Akyildiz, Hizir ^a   Muhtaroglu, Sebahattin ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Bacterial translocation; Colitis; Cytokine; Experimental; RANTES

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; ENDOTOXIN; METHIONINE; METHIONINE REGULATED UPON ACTIVATION, NORMAL T CELL EXPRESSED AND SECRETED; MYELOPEROXIDASE; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL TRANSLOCATION; BACTERIUM CULTURE; COLITIS; CONTROLLED STUDY; LIVER; LYMPH NODE; NONHUMAN; PORTAL VEIN BLOOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SPLEEN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL TRANSLOCATION; COLITIS; COLON; DISEASE MODELS, ANIMAL; MALE; NOXAE; RANTES; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID;

EID: 29944441837     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2005.10.005     Document Type: Article

References (37)

1. T.T. McDonald, G. Monteleone, S.L. Pender Recent developments in the immunology of inflammatory bowel disease Scand J Immunol 51 2000 2 9
2. K.R. Gardiner, M.I. Halliday, G.R. Barclay Significance of systemic endotoxaemia in inflammatory bowel disease Gut 36 1995 897 901
3. W. Wellmann, P.C. Fink, F. Benner Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid Gut 27 1986 814 820
4. N.S. Ambrose, M. Johnson, D.W. Burdon Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery Br J Surg 71 1984 623 625
5. M.N. Eade, B.N. Brooke Portal bacteraemia in cases of ulcerative colitis submitted to colectomy Lancet I 1969 1008 1009
6. R.J. Heddle, D.J.C. Shearman Serum antibodies to Escherichia coli in subjects with ulcerative colitis Clin Exp Immunol 38 1979 22 30
7. C.O. Olson, R.B. Sartor, G.S. Tennyson Experimental models of inflammatory bowel disease Gastroenterology 109 1995 1344 1367
8. M.N. Ajuebor, C.M. Hogaboam, S.L. Kunkel The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat J Immunol 166 2001 552 558
9. L. Mazzucchelli, C. Hauser, K. Zgraggen Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease J Pathol 178 1996 201 206
10. M. Baggiolini Chemokines and leukocyte traffic Nature 392 1998 565 568
11. A.M. Das, M.N. Ajuebor, R.J. Flower Contrasting roles for RANTES and macrophage inflammatory protein-1 a (MIP-1a) in a murine model of allergic peritonitis Clin Exp Immunol 117 1999 223 229
12. L. Mazzucchelli, C. Hauser, K. Zgraggen Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease J Pathol 178 1996 201 206
13. M. Bhatia, A.E. Proudfoot, T.N. Wells Treatment with Met-RANTES reduces lung injury in caerulein-induced pancreatitis Br J Surg 90 2003 698 704
14. A.E. Proudfoot, C.A. Power, A.J. Hoogewerf Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist J Biol Chem 271 1996 2599 2603
15. C. Gerard, J.L. Frossard, M. Bhatia Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury J Clin Invest 100 1997 2022 2027
16. G. McCormack, D. Moriarty, D.P. O'Donoghue Tissue cytokine and chemokine expression in inflammatory bowel disease Inflamm Res 50 2001 491 495
17. G.P. Morris, P.L. Beck, M.S. Herridge Hapten-induced model of chronic inflammation and ulceration in the rat colon Gastroenterology 96 1989 795 803
18. U. Panzer, A. Schneider, J. Wilken The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis Kidney Int 56 1999 2107 2115
19. A. Garcia-Lafuente, M. Antolin, F. Guarner Incrimination of anaerobic bacteria in the induction of experimental colitis Am J Physiol 272 1997 10 15
20. J.L. Wallace, W.K. Mac Naughton, G.P. Morris Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease Gastroenterology 96 1989 29 36
21. B.R. Macpherson, C.J. Pfeifer Experimental production of diffuse colitis in rats Digestion 17 1978 35 50
22. P.P. Bradley, D.A. Priebat, R.D. Christensen Measurement of cutaneous inflammation estimation of neutrophil content with an enzyme marker J Invest Dermatol 78 1982 206 209
23. B.M. Calkins, A.I. Mendelhoff The epidemiology of idiopathic inflammatory bowel disease J.B. Kirsner R.G. Shorter Inflammatory Bowel Disease 1995 Williams and Wilkins Baltimore, MD 31 68
24. R. Zamuner, N. Warrier, A.G. Buret Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction Gut 52 2003 1714 1720
25. R.D. Berg, A.W. Garlington Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model Infect Immun 23 1979 403 411
26. J.K. Stechmiller, D. Treloar, N. Allen Gut dysfunction in critically ill patients a review of the literature Am J Crit Care 6 1997 204 209
27. K.R. Gardiner, P.J. Erwin, N.H. Anderson Colonic bacteria and bacterial translocation in experimental colitis Br J Surg 80 1993 512 516
28. A.D. Luster Chemokines-chemotactic cytokines that mediate inflammation N Engl J Med 338 1998 436 445
29. R.P. MacDermott, I.R. Sanderson, H.C. Reinecker The central role of chemokines (chemotactic cytokines) in the immunopathogenesis of ulcerative colitis and Crohn's disease Inflamm Bowel Dis 4 1998 54 67
30. W.W. Agace, A.I. Roberts, L. Wu Human intestinal lamina propria and intraepithelial lymphocytes express receptors specific for chemokines induced by inflammation Eur J Immunol 30 2000 819 826
31. D.H. Adams, A.R. Lloyd Chemokines leucocyte recruitment and activation cytokines Lancet 349 1997 490 495
32. C.M. Lloyd, M.E. Dorf, A. Proudfoot Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis J Leukocyte Biol 62 1997 676 680
33. M.E. Blam, R.B. Stein, G.R. Lichtenstein Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease current and future perspectives Am J Gastroenterol 96 2001 1977 1997
34. L.Y. Kam, S.R. Targan TNF-alpha antagonists for the treatment of Crohn's disease Expert Opin Pharmacother 4 2000 615 622
35. E. Louis The immuno-inflammatory reaction in Crohn's disease and ulcerative colitis: characterisation, genetics and clinical application. Focus on TNF alpha Acta Gastroenterol Belg 64 2001 1 5
36. K.L. Worledge, R. Godiska, T.A. Barrett Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats Dig Dis Sci 45 2000 2298 2305
37. C.P. Braegger, S. Nicholls, S.M. Murch Tumor necrosis factor alpha in stool as a marker of intestinal inflammation Lancet 339 1992 89 91